Novel M₁ allosteric ligands: a patent review

Bibliography

• Filmore D. It's a GPCR world. Mod Drug Discov 2004;11:727-30
   Google Scholar
• Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989;12:148-51
   PubMed Web of Science ®Google Scholar
• Bonner TI. New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci 1989; suppl:11-15
   Google Scholar
• Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical innervation. Neurology 1998;51:S18-29
   Google Scholar
• Hansen R, Gartlehner G, Webb AP, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211-25
   PubMed Web of Science ®Google Scholar
• Rouse ST, Marino MJ, Potter LT, Muscarinic receptor sub-types involved in hippocampal circuits. Life Sci 1999;64:501-9
   Google Scholar
• Anagnostaras SG, Murpht GG, Hamilton SE, Selective cognitive disfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-8
   PubMed Web of Science ®Google Scholar
• Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 2004;44:423-50
   PubMed Web of Science ®Google Scholar
• Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther 2008;117:232-43
   PubMed Web of Science ®Google Scholar
• Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia. J Neurochem 2008;107:1188-95
   PubMed Web of Science ®Google Scholar
• Jones CK, Buyn N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2011;1:1-27
   Google Scholar
• Bridges TM, LeBois EP, Hopkins CR, The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect 2010;23:229-40
   PubMedGoogle Scholar
• Sur C, Kinney GG. Selective targeting of muscarinic receptors:novel therapeutic approaches for psychotic disorders. Curr Neuropharmacol 2005;3:63-71
   Google Scholar
• Sellin AK, Shad M, Tamminga C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 2008;13:985-96
   Web of Science ®Google Scholar
• Fisher A. Cholingergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 2012;120:22-33
   PubMed Web of Science ®Google Scholar
• Greenlee W, Clader J, Asbersom T, Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Il Farmaco 2001;56:247-50
   PubMedGoogle Scholar
• Bodick NC, Offen WW, Levey AI, Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavorial symptoms in Alzheimer. Dis Arch Neurol 1997;54:465-73
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Whitesitt CA, Shannon HE. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997;40:158-70
   Web of Science ®Google Scholar
• Lieberman JA, Javitch JA, Moore H, Cholinergic agonits as novel treatments for schizophrenia: the promise of rational drug development for pyschiatry. Am J Physchiatry 2008;165:931-6
   PubMed Web of Science ®Google Scholar
• Fisher A. Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease modifying agents for Alzheimer's disease. Neurotherapeutics 1999;12:197-214
   Google Scholar
• Heinrich JN, Butera JA, Carrick T, Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1 preferring agonists. Eur J Pharmacol 2009;605:53-6
   PubMedGoogle Scholar
• Langmead CJ, Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Neuropsychopharmacology 2006;27:475-81
   Google Scholar
• Digby GJ, Conn PJ, Lindsley CW. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Curr Opin Drug Disc Dev 2010;13:587-94
   Google Scholar
• Kenakin T. Functional selectivity in GPCR modulator screening. Comb Chem High Throughput Screen 2008;11:337-43
   PubMed Web of Science ®Google Scholar
• Conn PJ, Christopoulus A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
   PubMed Web of Science ®Google Scholar
• Spalding TA, Trotter C, Skjaerbaek N, Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 2002;61:1297-302
   PubMedGoogle Scholar
• Sur C, Mallorga PJ, Wittmann M, N-desmethylclozapine, an allosteric agonist at muscarinic M1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci 2003;23:13674-9
   Google Scholar
• MaxCyte Corp. Synthesis and Isolation of solid N-desmethylclozapine and crystaline forms thereof. US282200; 2005
   Google Scholar
• Bridges TM, Brady AE, Kennedy JP, Synthesis and SAR of analogues of the M1 allosteric agonist. TBPB. Part I:exploration of alternative benzyl and privileged structure motifs. Bioorg Med Chem Lett 2008;18:5439-42
   Google Scholar
• Jones CK, Brady AE, Davis AA, Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008;41:10422-33
   Google Scholar
• Spalding TA, Ma JN, Ott TR, Structural requirements of transmembrane domain 3 for activation by the muscarinic receptor antagonists AC-42, AC-260484, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 2006;70:1974-83
   Google Scholar
• Langmead CJ, Fry VA, Forbes IT, Proving the molecular mechanism of interaction between AC-42 and the M1 muscarinic receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006;69:236-46
   PubMedGoogle Scholar
• Jacobson MA, Kreatsoulas C, Pascarella DM, The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-13,-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetycholine orthosteric site. Mol Pharmacol 2010;78:648-57
   PubMed Web of Science ®Google Scholar
• Acadia Corp. Compounds with activity on muscarinic receptors. US0144285; 2003
   Google Scholar
• Bradley SR, Lameh J, Ohrmund L, AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010;58:365-73
   Google Scholar
• Acadia Corp. Benzimidazolone derivatives as muscarinic agents. US0216840; 2010
   Google Scholar
• Acadia Corp. Benzimidazolone derivatives as muscarinic agents. US0205785; 2006
   Google Scholar
• Acadia Corp. Muscarinic agonists. US0113357; 2005
   Google Scholar
• Lundbeck Corp. Novel heterobicyclic carboxamides as M1 agonists. WO0106534; 2009
   Google Scholar
• Sams AG, Hentzer M, Mikkelsen GK, Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. J Med Chem 2010;53:6386-97
   Google Scholar
• Lundbeck Corp. Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as M1 agonists. WO124882; 2009
   Google Scholar
• Lundbeck Corp. Novel 1,3-dihydro-benzoimidazol-2-ones as M1 agonist. WO124883; 2009
   Google Scholar
• Marlo JE, Niswender CM, Days EL, Discovery and Characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharm 2009;75:577-88
   Google Scholar
• Vanderbilt University. Amidobipiperidinecarboxylate M1 allosteric agonists, analogs, and derivatives thereof, and methods of making and using same. WO096703; 2010
   Google Scholar
• Lebois EP, Digby GJ, Sheffler DJ, Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett 2011;21:6451-5
   Google Scholar
• Vanderbilt University. Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same. WO087812; 2011
   Google Scholar
• Vanderbilt University. Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective M1 agonists and methods of making and using same. WO112825; 2011
   Google Scholar
• Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of the muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009;30:148-55
   PubMed Web of Science ®Google Scholar
• Bridges TM, Kennedy JP, Noetzel MJ, Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM. Bioorg Med Chem Lett 2010;20:1972-5
   Google Scholar
• Vanderbilt University. Indole compounds as positive allosteric modulators of the muscarinic receptor. WO0163280; 2011
   Google Scholar
• Reid PR, Bridges TM, Sheffler DJ, Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett 2011;21:2697-701
   Google Scholar
• Merck & Co. Treatment of psychosis with a muscarinic M1 receptor ectopic activator. WO073639; 2004
   Google Scholar
• Merck & Co. Benzyl-substituted quinolone M1 receptor positive allosteric modulators. WO002621; 2008
   Google Scholar
• Merck & Co. Benzyl substituted quinolone M1 receptor positive allosteric modulators. WO002621; 2008
   Google Scholar
• Ma L, Seager M, Wittmann M, Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 2009;106:15950-5
   PubMed Web of Science ®Google Scholar
• Merck & Co. Quinolone M1 receptor positive allosteric modulators. TW40814; 2008
   Google Scholar
• Merck & Co. Quinolone M1 receptor positive allosteric modulators. WO134668; 2009
   Google Scholar
• Merck & Co. N-Heterocyclic M1 receptor positive allosteric modulators. EP2312949; 2008
   Google Scholar
• Merck & Co. Fused heterocyclic M1 receptor positive allosteric modulators. EP2355659; 2008
   Google Scholar
• Kuduk SD, Di Marco CN, Cofre V, Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding. Bioorg Med Chem Lett 2009;19:657-60
   Google Scholar
• Kuduk SD, Di Marco CN, Cofre V, N-heterocyclic derived M1 positive allosteric modulators. Bioorg Med Chem Lett 2010;20:1334-7
   PubMed Web of Science ®Google Scholar
• Kuduk SD, Di Marco CN, Chang RK, Fused heterocyclic M1 positive allosteric modulators. Bioorg Med Chem Lett 2011;20:2769-72
   Google Scholar
• Merck & Co. Fused Pyridone M1 receptor positive allosteric modulators. WO102588; 2009
   Google Scholar
• Kuduk SD, DiPardo RM, Beshore DC, Hydroxy cycloalkyl fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorg Med Chem Lett 2010;20:2538-41
   Google Scholar
• Kuduk SD, Di Marco CN, Chang RK, Heterocyclic Fused Pyridone Carboxylic Acid M1 Positive Allosteric Modulators. Bioorg Med Chem Lett 2010;20:533-2537
   Google Scholar
• Merck & Co. Quinolizidinone M1 receptor positive allosteric modulators. WO042347; 2010
   Google Scholar
• Merck & Co. Quinolizidinone M1 receptor positive allosteric modulators. US0112077; 2011
   Google Scholar
• Kuduk SD, Chang RK, Di Marco CN, Quinolizidinone Carboxylic Acids as CNS Penetrant, Selective M1 Allosteric Muscarinic Receptor Modulators. ACS Med Chem Lett 2010;1:263-7
   PubMed Web of Science ®Google Scholar
• Merck & Co. Quinolizidinone M1 receptor positive allosteric modulators. US046145; 2011
   Google Scholar
• Merck & Co. Quinolizidinone M1 receptor positive allosteric modulators. (US or WO117283); 2009
   Google Scholar
• Kuduk SD, Chang RK, Di Marco CN, Quinolizidinone carboxylic acid selective M1 allosteric moduators: SAR in the piperidine series. 059773; Bioorg Med Chem Lett 2011;21:1710-15
   Google Scholar
• Merck & Co. Quinolizidinone M1 receptor positive allosteric modulators. WO051715; 2009
   Google Scholar
• Kuduk SD, Chang RK, Di Marco CN, Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. J Med Chem 2011;13:4773-80
   Google Scholar
• Merck & Co. Quinolizidinone carboxamide M1 receptor positive allosteric modulators. WO062853; 2011
   Google Scholar
• Merck & Co. Naphthalene carboxamide M1 receptor positive allosteric modulators. WO149801; 2011
   Google Scholar
• Merck & Co. Aryl methyl benzoquinazoline M1 receptor positive allosteric modulators. WO059773; 2010
   Google Scholar
• Merck & Co. Pyranyl aryl methyl benzoquinazoline M1 receptor positive allosteric modulators. WO025851; 2011
   Google Scholar
• Merck & Co. Amino benzoquinazoline M1 receptor positive allosteric modulators. WO084371; 2011
   Google Scholar
• Merck & Co. Pyridobenzoquinazoline M1 receptor positive allosteric modulators. WO075371; 2011
   Google Scholar
• Merck & Co. Isoindolone M1 receptor positive allosteric modulators. WO003147; 2012
   Google Scholar
• Merck & Co. Isoindolone M1 receptor positive allosteric modulators. WO096338; 2010
   Google Scholar
• Merck & Co. Isoindolone M1 receptor positive allosteric modulators. WO123716; 2010
   Google Scholar
• Merck & Co. Isoindolone M1 receptor positive allosteric modulators. WO049731; 2011
   Google Scholar
• Langmead CJ, Austin NE, Branch CL, Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharm 2008;154:1104-15
   PubMed Web of Science ®Google Scholar
• Budzik B, Garzya V, Shi D, Novel N-substituted benzimidazolones as potent, selective, CNS_penetrant, and orally active M1 mAChR agonists. ACS Med Chem Lett 2010;1:244-8
   PubMed Web of Science ®Google Scholar
• GSK. Compounds which have activity at M1 receptor and their uses in medicine. WO036718; 2007
   Google Scholar
• GSK. Benzimidazolones which have activity at M1 receptor and their uses in medicine. WO107567; 2007
   Google Scholar
• Huiban M, Pampols-Maso S, Passchier J. Fully automated synthesis of the M1 receptor agonist [11C]GSK1034702 for clinical use on an Eckert & Ziegler Modular Lab system. Appl Radiat Isot 2011;69:1390-4
   Google Scholar
• GSK. Compounds which have activity at M1 receptor and their uses in medicine. WO036715; 2007
   Google Scholar
• GSK. Benzoimidazolone derivatives which have activity at M1 receptor and their uses in medicine. WO1197712; 2008
   Google Scholar
• GSK. 1-(1-Cyclobutyl-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one derivatives which have activity on the ML receptor and their uses as medicine. WO119720; 2008
   Google Scholar
• GSK. 1-(1-Cyclohexyl-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one derivatives which have activity on the M1 receptor and their uses in medicine. WO119716; 2008
   Google Scholar
• Johnson DJ, Forbes IT, Watson SP. The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. Bioorg Med Chem Lett 2010;20:5434-8
   Google Scholar
• GSK. Compounds which have activity at the M1 receptor and their uses in medicine. WO037294; 2009
   Google Scholar